NovoCure NVCR Debt issuance costs and discount amortization
Debt issuance costs and discount amortization at other companies
Other financials
Where this comes from
Reported directly by NovoCure in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfDebtDiscountPremium.
The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about NovoCure's debt issuance costs and discount amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NovoCure's debt issuance costs and discount amortization?
- NovoCure (NVCR) reported debt issuance costs and discount amortization of -$2.62M in Q1 2026.
- How has NovoCure's debt issuance costs and discount amortization changed year-over-year?
- NovoCure's debt issuance costs and discount amortization increased by 60.7% year-over-year, from -$6.65M to -$2.62M.
- What is the long-term trend for NovoCure's debt issuance costs and discount amortization?
- Over 4 years (2021 to 2025), NovoCure's debt issuance costs and discount amortization has grown at a 65.5% compound annual growth rate (CAGR), from $3.1M to -$23.26M.
- What does debt issuance costs and discount amortization mean?
- Reflects the non-cash periodic allocation of debt issuance costs and original issue discounts over the life of the debt instrument. This adjustment reconciles the difference between the cash interest paid and the effective interest expense recognized in the income statement. It provides insight into the true cost of borrowing and the impact of financing structures on long-term profitability.